Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX - Get Free Report)'s stock price was down 5.4% on Wednesday . The company traded as low as $3.08 and last traded at $3.11. Approximately 7,303 shares traded hands during mid-day trading, a decline of 53% from the average daily volume of 15,641 shares. The stock had previously closed at $3.29.
Eupraxia Pharmaceuticals Price Performance
The firm has a market capitalization of $86.29 million and a P/E ratio of -3.91. The firm's fifty day moving average price is $2.61 and its 200-day moving average price is $2.68.
Eupraxia Pharmaceuticals (NASDAQ:EPRX - Get Free Report) last posted its quarterly earnings data on Wednesday, August 7th. The company reported ($0.17) EPS for the quarter.
Institutional Investors Weigh In On Eupraxia Pharmaceuticals
An institutional investor recently bought a new position in Eupraxia Pharmaceuticals stock. 180 Wealth Advisors LLC bought a new stake in Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX - Free Report) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 13,000 shares of the company's stock, valued at approximately $34,000.
About Eupraxia Pharmaceuticals
(
Get Free Report)
Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company's lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee.
Recommended Stories
Before you consider Eupraxia Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eupraxia Pharmaceuticals wasn't on the list.
While Eupraxia Pharmaceuticals currently has a "Strong Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
